Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV- infected women with advanced disease: Results of pediatric AIDS clinical trials group protocol 185

E. Richard Stiehm, John S. Lambert, Lynne M. Mofenson, James Bethel, Jean Whitehouse, Robert Nugent, Moye John, Mary Glenn Fowler, Bonnie J. Mathieson, Patricia Reichelderfer, George J. Nemo, James Korelitz, William A. Meyer, Christine V. Sapan, Eleanor Jimenez, Jorge Gandia, Gwendolyn B Scott, Mary Jo O'Sullivan, Andrea Kovacs, Alice StekWilliam T. Shearer, Hunter Hammill

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Pediatric AIDS Clinical Trials Group protocol 185 evaluated whether zidovudine combined with human immunodeficiency virus (HIV) hyperimmune immunoglobulin (HIVIG) infusions administered monthly during pregnancy and to the neonate at birth would significantly lower perinatal HIV transmission compared with treatment with zidovudine and intravenous immunoglobulin (IVIG) without HIV antibody. Subjects had baseline CD4 cell counts ≤500/ μL (22% had counts <200/μL) and required zidovudine for maternal health (24% received zidovudine before pregnancy). Transmission was associated with lower maternal baseline CD4 cell count (odds ratio, 1.58 per 100-cell decrement; P = .005; 10.0% vs. 3.6% transmission for count <200 vs. ≥200/μL) but not with time of zidovudine initiation (5.6% vs. 4.8% if started before vs. during pregnancy; P = .75). The Kaplan-Meier transmission rate for HIVIG recipients was 4.1% (95% confidence interval, 1.5%-6.7%) and for IVIG recipients was 6.0% (2.8%-9.1%) (P = .36). The unexpectedly low transmission confirmed that zidovudine prophylaxis is highly effective, even for women with advanced HIV disease and prior zidovudine therapy, although it limited the study's ability to address whether passive immunization diminishes perinatal transmission.

Original languageEnglish
Pages (from-to)567-575
Number of pages9
JournalJournal of Infectious Diseases
Volume179
Issue number3
DOIs
StatePublished - Dec 1 1999

Fingerprint

Zidovudine
Clinical Protocols
Immunoglobulins
Acquired Immunodeficiency Syndrome
Clinical Trials
HIV
Pediatrics
Intravenous Immunoglobulins
CD4 Lymphocyte Count
Pregnancy
Passive Immunization
Virus Diseases
Odds Ratio
Mothers
Parturition
Newborn Infant
Confidence Intervals
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV- infected women with advanced disease : Results of pediatric AIDS clinical trials group protocol 185. / Stiehm, E. Richard; Lambert, John S.; Mofenson, Lynne M.; Bethel, James; Whitehouse, Jean; Nugent, Robert; John, Moye; Fowler, Mary Glenn; Mathieson, Bonnie J.; Reichelderfer, Patricia; Nemo, George J.; Korelitz, James; Meyer, William A.; Sapan, Christine V.; Jimenez, Eleanor; Gandia, Jorge; Scott, Gwendolyn B; O'Sullivan, Mary Jo; Kovacs, Andrea; Stek, Alice; Shearer, William T.; Hammill, Hunter.

In: Journal of Infectious Diseases, Vol. 179, No. 3, 01.12.1999, p. 567-575.

Research output: Contribution to journalArticle

Stiehm, ER, Lambert, JS, Mofenson, LM, Bethel, J, Whitehouse, J, Nugent, R, John, M, Fowler, MG, Mathieson, BJ, Reichelderfer, P, Nemo, GJ, Korelitz, J, Meyer, WA, Sapan, CV, Jimenez, E, Gandia, J, Scott, GB, O'Sullivan, MJ, Kovacs, A, Stek, A, Shearer, WT & Hammill, H 1999, 'Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV- infected women with advanced disease: Results of pediatric AIDS clinical trials group protocol 185', Journal of Infectious Diseases, vol. 179, no. 3, pp. 567-575. https://doi.org/10.1086/314637
Stiehm, E. Richard ; Lambert, John S. ; Mofenson, Lynne M. ; Bethel, James ; Whitehouse, Jean ; Nugent, Robert ; John, Moye ; Fowler, Mary Glenn ; Mathieson, Bonnie J. ; Reichelderfer, Patricia ; Nemo, George J. ; Korelitz, James ; Meyer, William A. ; Sapan, Christine V. ; Jimenez, Eleanor ; Gandia, Jorge ; Scott, Gwendolyn B ; O'Sullivan, Mary Jo ; Kovacs, Andrea ; Stek, Alice ; Shearer, William T. ; Hammill, Hunter. / Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV- infected women with advanced disease : Results of pediatric AIDS clinical trials group protocol 185. In: Journal of Infectious Diseases. 1999 ; Vol. 179, No. 3. pp. 567-575.
@article{0ff8a67e76e5462d99f14a283225be91,
title = "Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV- infected women with advanced disease: Results of pediatric AIDS clinical trials group protocol 185",
abstract = "Pediatric AIDS Clinical Trials Group protocol 185 evaluated whether zidovudine combined with human immunodeficiency virus (HIV) hyperimmune immunoglobulin (HIVIG) infusions administered monthly during pregnancy and to the neonate at birth would significantly lower perinatal HIV transmission compared with treatment with zidovudine and intravenous immunoglobulin (IVIG) without HIV antibody. Subjects had baseline CD4 cell counts ≤500/ μL (22{\%} had counts <200/μL) and required zidovudine for maternal health (24{\%} received zidovudine before pregnancy). Transmission was associated with lower maternal baseline CD4 cell count (odds ratio, 1.58 per 100-cell decrement; P = .005; 10.0{\%} vs. 3.6{\%} transmission for count <200 vs. ≥200/μL) but not with time of zidovudine initiation (5.6{\%} vs. 4.8{\%} if started before vs. during pregnancy; P = .75). The Kaplan-Meier transmission rate for HIVIG recipients was 4.1{\%} (95{\%} confidence interval, 1.5{\%}-6.7{\%}) and for IVIG recipients was 6.0{\%} (2.8{\%}-9.1{\%}) (P = .36). The unexpectedly low transmission confirmed that zidovudine prophylaxis is highly effective, even for women with advanced HIV disease and prior zidovudine therapy, although it limited the study's ability to address whether passive immunization diminishes perinatal transmission.",
author = "Stiehm, {E. Richard} and Lambert, {John S.} and Mofenson, {Lynne M.} and James Bethel and Jean Whitehouse and Robert Nugent and Moye John and Fowler, {Mary Glenn} and Mathieson, {Bonnie J.} and Patricia Reichelderfer and Nemo, {George J.} and James Korelitz and Meyer, {William A.} and Sapan, {Christine V.} and Eleanor Jimenez and Jorge Gandia and Scott, {Gwendolyn B} and O'Sullivan, {Mary Jo} and Andrea Kovacs and Alice Stek and Shearer, {William T.} and Hunter Hammill",
year = "1999",
month = "12",
day = "1",
doi = "10.1086/314637",
language = "English",
volume = "179",
pages = "567--575",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV- infected women with advanced disease

T2 - Results of pediatric AIDS clinical trials group protocol 185

AU - Stiehm, E. Richard

AU - Lambert, John S.

AU - Mofenson, Lynne M.

AU - Bethel, James

AU - Whitehouse, Jean

AU - Nugent, Robert

AU - John, Moye

AU - Fowler, Mary Glenn

AU - Mathieson, Bonnie J.

AU - Reichelderfer, Patricia

AU - Nemo, George J.

AU - Korelitz, James

AU - Meyer, William A.

AU - Sapan, Christine V.

AU - Jimenez, Eleanor

AU - Gandia, Jorge

AU - Scott, Gwendolyn B

AU - O'Sullivan, Mary Jo

AU - Kovacs, Andrea

AU - Stek, Alice

AU - Shearer, William T.

AU - Hammill, Hunter

PY - 1999/12/1

Y1 - 1999/12/1

N2 - Pediatric AIDS Clinical Trials Group protocol 185 evaluated whether zidovudine combined with human immunodeficiency virus (HIV) hyperimmune immunoglobulin (HIVIG) infusions administered monthly during pregnancy and to the neonate at birth would significantly lower perinatal HIV transmission compared with treatment with zidovudine and intravenous immunoglobulin (IVIG) without HIV antibody. Subjects had baseline CD4 cell counts ≤500/ μL (22% had counts <200/μL) and required zidovudine for maternal health (24% received zidovudine before pregnancy). Transmission was associated with lower maternal baseline CD4 cell count (odds ratio, 1.58 per 100-cell decrement; P = .005; 10.0% vs. 3.6% transmission for count <200 vs. ≥200/μL) but not with time of zidovudine initiation (5.6% vs. 4.8% if started before vs. during pregnancy; P = .75). The Kaplan-Meier transmission rate for HIVIG recipients was 4.1% (95% confidence interval, 1.5%-6.7%) and for IVIG recipients was 6.0% (2.8%-9.1%) (P = .36). The unexpectedly low transmission confirmed that zidovudine prophylaxis is highly effective, even for women with advanced HIV disease and prior zidovudine therapy, although it limited the study's ability to address whether passive immunization diminishes perinatal transmission.

AB - Pediatric AIDS Clinical Trials Group protocol 185 evaluated whether zidovudine combined with human immunodeficiency virus (HIV) hyperimmune immunoglobulin (HIVIG) infusions administered monthly during pregnancy and to the neonate at birth would significantly lower perinatal HIV transmission compared with treatment with zidovudine and intravenous immunoglobulin (IVIG) without HIV antibody. Subjects had baseline CD4 cell counts ≤500/ μL (22% had counts <200/μL) and required zidovudine for maternal health (24% received zidovudine before pregnancy). Transmission was associated with lower maternal baseline CD4 cell count (odds ratio, 1.58 per 100-cell decrement; P = .005; 10.0% vs. 3.6% transmission for count <200 vs. ≥200/μL) but not with time of zidovudine initiation (5.6% vs. 4.8% if started before vs. during pregnancy; P = .75). The Kaplan-Meier transmission rate for HIVIG recipients was 4.1% (95% confidence interval, 1.5%-6.7%) and for IVIG recipients was 6.0% (2.8%-9.1%) (P = .36). The unexpectedly low transmission confirmed that zidovudine prophylaxis is highly effective, even for women with advanced HIV disease and prior zidovudine therapy, although it limited the study's ability to address whether passive immunization diminishes perinatal transmission.

UR - http://www.scopus.com/inward/record.url?scp=18544391179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18544391179&partnerID=8YFLogxK

U2 - 10.1086/314637

DO - 10.1086/314637

M3 - Article

C2 - 9952362

AN - SCOPUS:18544391179

VL - 179

SP - 567

EP - 575

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -